UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Volltextzugriff (PDF)

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab

PloS one, 2013-02, Vol.8 (2), p.e56112-e56112

2013

Volltextzugriff (PDF)

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

Journal of thoracic oncology, 2014-10, Vol.9 (10), p.1523-1531

2014

Volltextzugriff (PDF)

randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

Cancer chemotherapy and pharmacology, 2009-11, Vol.64 (6), p.1139-1148

2009

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

Clinical cancer research, 2004-08, Vol.10 (15), p.4913-4921

2004

Volltextzugriff (PDF)

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Clinical cancer research, 2007-02, Vol.13 (4), p.1238-1245

2007

Volltextzugriff (PDF)

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Cancer chemotherapy and pharmacology, 2007-11, Vol.60 (6), p.799-809

2007

Volltextzugriff (PDF)

Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat

Pharmaceutical research, 1998-04, Vol.15 (4), p.599-605

1998

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer

Clinical cancer research, 2002-07, Vol.8 (7), p.2116-2122

2002

Volltextzugriff (PDF)

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Cancer chemotherapy and pharmacology, 2008-06, Vol.62 (1), p.97-109

2008

Volltextzugriff (PDF)

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3082-3082

2023

Volltextzugriff (PDF)

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A66-A66

2023

Volltextzugriff (PDF)

Increased brain P-glycoprotein in morphine tolerant rats

Life sciences (1973), 1999-12, Vol.66 (4), p.PL47-PL51

1999

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Clinical cancer research, 2011-03, Vol.17 (5), p.1131-1139

2011

Volltextzugriff (PDF)

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR -mutant lung cancers

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7530-7530

2012

Volltextzugriff (PDF)

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor ( EGFR ) activating mutation(s)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS8123-TPS8123

2013

Volltextzugriff (PDF)

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS7615-TPS7615

2012

Volltextzugriff (PDF)

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells

Biochemical pharmacology, 1999-09, Vol.58 (6), p.951-957

1999

Volltextzugriff (PDF)

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Anti-cancer drugs, 1998-08, Vol.9 (7), p.611-619

1998

Volltextzugriff (PDF)

Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat

Drug metabolism and disposition, 1999-07, Vol.27 (7), p.827

1999

Volltextzugriff (PDF)

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

Clinical investigation, 2013-01, Vol.3 (1), p.29-35

2013

Volltextzugriff (PDF)

P-glycoprotein-mediated disposition of morphine in the central nervous system

Letrent, Stephen Paul

1998

Volltextzugriff (PDF)

Muckraking Novels: The Search for Another Paradigm

Critical Management Studies at Work, 2009

2009

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(24)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Biological And Medical Sciences
(12)
Humans
(12)
Medical Sciences
(12)
Oncology
(12)
Adult
(11)
Aged
(11)
Female
(11)
Middle Aged
(11)
Pharmacology. Drug Treatments
(11)
Male
(10)
Antineoplastic Agents
(9)
Tumors
(9)
Pharmacology & Pharmacy
(8)
Lung Neoplasms - Drug Therapy
(6)
Area Under Curve
(5)
Dose-Response Relationship, Drug
(5)
Erlotinib Hydrochloride
(5)
Multiple Tumors. Solid Tumors. Tumors In Childhood
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat

Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Increased brain P-glycoprotein in morphine tolerant rats

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR -mutant lung cancers

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor ( EGFR ) activating mutation(s)

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

P-glycoprotein-mediated disposition of morphine in the central nervous system

Muckraking Novels: The Search for Another Paradigm

Suchergebnisse filtern